The biotech landscape is shifting again with news that CARGO Therapeutics, the innovative CAR T-cell therapy developer, is poised to be absorbed by Concentra Biosciences. According to CARGO Therapeutics, Concentra will acquire CARGO for $4.379 in cash per share plus a contingent value right (CVR). They're set to receive the upfront money and a cut of any future gains from asset sales within two years of closing. The all-cash tender offer is set to commence by July 2, with an expected close the following month, provided most shares are tendered and other conditions fall into place.
It's a strategic move for Concentra Biosciences, a company swiftly gaining a reputation for adeptly swooping in on biotech firms facing headwinds. This acquisition seems part of a broader pattern, as Concentra has taken under its wing multiple Bay Area biotech companies that were on the brink. Concentra's parent company, Tang Capital Management, has notably stayed out of the limelight, not responding to press inquiries despite having investments across a wide spectrum of businesses, as SFGATE reports. Their extensive portfolio boasts over $1.8 billion according to recent filings, which include both mainstream companies and a variety of biotech endeavors.
CARGO's journey has been turbulent, with its valuation diving early this year due to disappointing clinical trial results and subsequent staff layoffs. By cutting drug development and slashing the workforce, they sought to tighten the focus on value for shareholders and patients. The deal with Concentra, if successful, will ensure shareholders garner their share of CARGO’s $362 million in assets, with Concentra in line to potentially sweep up to $217.5 million of the company's cash stash.
